In conclusion, we suggest that the terms “anoctaminopathy” or “ANO5 myopathy” better define a heterogeneous disease caused by mutations in the ANO5 gene, irrespective of the first proximal (LGMD2L), distal symptoms (Miyoshi myopathy) or characterized by other myopathic features. The gene discussed is ANO5; the disease is autosomal recessive limb-girdle muscular dystrophy type 2L.